Showing 1041-1050 of 1211 results for "".
- Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meetinghttps://modernod.com/news/kiora-pharmaceuticals-announces-the-acceptance-of-three-abstracts-at-the-2023-arvo-annual-meeting/2481458/Kiora Pharmaceuticals announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, April 23-27, 2023. Further results from each of these three studies will be reported at the conference.<
- Phase 1/2a Results of Lineage Cell's Retinal Pigment Epithelium Cell Transplant Therapy to Be Featured at ARVO Annual Meetinghttps://modernod.com/news/phase-12a-results-of-lineage-cells-retinal-pigment-epithelium-cell-transplant-therapy-to-be-featured-at-arvo-annual-meeting/2481451/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes in addition to visual data from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.
- Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-sponsors-uni-rare-natural-history-study-for-people-with-inherited-retinal-diseases/2481239/Opus Genetics announced the company will co-sponsor the Uni-Rare Study, a new natural history study for approximately 1,500 people with mutations in one of more than 300 rare genes associated with inherited retinal diseases (IRDs). The two-part Uni-Rare Study is being launched to charac
- Clearside: Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platformhttps://modernod.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/Clearside Biomedical announced that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons. “These data presenta
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul
- Thea Pharma Announces Activities and Events at the Upcoming American Academy of Ophthalmology (AAO) Annual Meetinghttps://modernod.com/news/thea-pharma-announces-activities-and-events-at-the-upcoming-american-academy-of-ophthalmology-aao-annual-meeting/2481108/Thea Pharma announced that the company will attend and participate in a number of meetings and events taking place at or in association with the American Academy of Ophthalmology Meeting, being held Sept. 30 to Oct. 3 at McCormick Place in Chicago. Thea will exhibit its flagship product
- Glaukos Licenses Iveena’s Investigational Keratoconus Therapyhttps://modernod.com/news/glaukos-licenses-iveenas-investigational-keratoconus-therapy/2481044/Glaukos has acquired an exclusive global license to develop and commercialize iVeena Delivery Systems' investigational pharmacologic treatment for keratoconus, IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with development
- Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseaseshttps://modernod.com/news/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/2480977/Avista Therapeutics, which recently launched as a spinout of the University of Pittsburgh Medical Center (UPMC), announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated
- Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meetinghttps://modernod.com/news/ocuphire-announces-late-breaking-paper-for-nyxol-for-reversal-of-dilation-indication-at-annual-asrs-meeting/2480950/Ocuphire Pharma today announced six presentations in July at meetings of the American-European Congress of Ophthalmic Surgery (AECOS), American Society of Retina Specialists (ASRS), Ophthalmology Innovation Summit (OIS), and the Octane and National Medical Association (NMA). At ASR
- Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to Iluvien Use for IOP Outcomeshttps://modernod.com/news/phase-4-paladin-study-confirms-positive-predictive-value-of-corticosteroid-course-prior-to-iluvien-use-for-iop-outcomes/2480855/Alimera Sciences announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the Iluvien U.S. label to mitigate the risk of uncontrolled IOP elevation. These results were presented at the annual Association for Researc